factors, such as hypercholesterolemia and hypertension, but do not directly target mechanisms that drive atherosclerotic processes. The lack of mechanism-based interventions is 1 reason why the global burden of atherosclerotic cardiovascular disease continues to rise.
As a first step towards mechanism-based interventions, new approaches to identify putative candidates for therapeutic development are necessary. To this end, we previously conducted a systems analysis of genetic association data from CAD cases and controls (CARDIOGRAM consortium [Coronary Artery Disease Genome-Wide Replication and Meta Analysis] 3 ). Through pathway enrichment analyses, we identified disease-associated pathways that were enriched for CAD-associated polymorphisms in their component genes. 4 One key finding was the identification of a proprotein convertase of the PCSK (proprotein convertase subtilisin/kexin) family, FURIN, as a hub gene shared across 6 of 32 replicated CAD-associated pathways, 4 making FURIN an attractive target for further validation in atherosclerosis.
FURIN (PCSK3) is a member of the proprotein convertase family that cleave multiple secretory protein precursors at specific single or paired basic amino acids. Furin knockout mice die at embryonic day 11 because of cardiac ventral closure defects and hemodynamic insufficiency. 5 However, Furin +/− mice are viable, and appear relatively normal, suggesting that ≈50% of FURIN is sufficient to perform most of its critical functions.
FURIN has been implicated in several diseases. In cancer, treatment with FURIN inhibitors reduced various tumors and metastases. 6, 7 FURIN expression is increased in the cartilage of patients with osteoarthritis, and treatment of mouse models of arthritis with FURIN inhibitors decreased inflammation and arthritis 8, 9 . FURIN inhibition also reduced viral infections in in vitro models. 10, 11 FURIN expression is increased in several cell types in human atherosclerotic lesions. 12 In addition, FURIN expression increased with increasing lesion severity in humans. 13 Liver-specific inhibition of FURIN in mice led to a decrease in atherosclerotic lesions, 14 and FURIN levels were correlated with cardiovascular complications in type 2 diabetics. 15 As well, a large-scale association analysis identified a single nucleotide polymorphism, rs17514846, in FURIN, as a risk factor for CAD. 16 Together, these findings suggest a role for FURIN in atherosclerotic cardiovascular disease.
A direct investigation of FURIN function using knockout mice models is difficult because mice with targeted deletions in Furin die in utero. 5 However, chemical and peptide-based FURIN inhibitors have been developed and extensively tested in viral and bacterial infections 17 and various types of cancers. 6, 18 These inhibitors show significant efficacy in inhibiting FURIN in multiple systems and are commonly used as tool compounds to probe the function of FURIN in cellular and animal models. [19] [20] [21] [22] In this study, we utilize inhibition as well as overexpression of FURIN in vivo and show that systemic FURIN levels are directly associated with atherosclerotic lesion progression in mouse models of atherosclerotic cardiovascular disease.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. Please see the Major Resources Table in the online-only Data Supplement.
Pathway Enrichment and Gene Expression Omnibus Analyses
To identify novel associations between established biological mechanisms and CAD, we performed a 2-stage pathway-based gene set enrichment analysis of 16 genome-wide association study datasets for CAD (available through the CARDIOGRAM consortium). Pathway enrichment analysis was conducted via the i-GSEA4GWAS (http://gsea4gwas.psych.ac.cn/inputPage.jsp) tool 23 by querying the Reactome pathway database. 24 From a meta-analyzed discovery cohort of 7 CAD genome-wide association study datasets (9889 cases/11 089 controls), nominally significant pathways were tested for replication in a meta-analysis of 9 additional studies (15 502 cases/55 730 controls).
To examine FURIN gene expression levels in atherosclerosis-relevant samples from human sources, we screened the Gene Expression Omnibus for human studies identified by the keywords macrophages, vascular endothelial cells, vascular smooth muscle cells, and atherosclerotic plaques. 18 microarray studies (Affymetrix and Illumina platforms), encompassing 570 samples were ultimately retrieved and analyzed. We queried the expression of FURIN and other proprotein convertases in samples from the different biological sources. To enable comparisons between diverse Gene Expression Omnibus datasets, the expression values from each study were converted into quintiles with Q1 representing the upper 20% and Q5 the bottom 20% of all expression values.
Western-Type Diet Fed Ldlr −/−

Model of Atherosclerosis
All experiments were approved by the Biomedical Sciences Institute Singapore Institutional Animal Care Committee and adhered to the Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies by the American Heart Association. 25 Thirtytwo male Ldlr −/− mice (C57BL/6JInv, Jackson Laboratory) on a 12-hour light-dark cycle were maintained on chow diet (1324_mod-ified, Altromin GmbH & Co) until 12 weeks of age, followed by a Western-type diet (WTD; D12079B, Research Diets, NJ) for 8 weeks. Half the mice were injected intraperitoneally with 1x PBS and the other half with 100 μg/kg of FURIN inhibitor (α-1-PDX [α1-antitrypsin Portland], RP-070; Thermo Fisher Scientific), twice per week, for 8 weeks in conjunction with the WTD feeding. The mice had free access to food and water except during a 4 to 5 hours fast period before blood sample collection. Mice were anesthetized at 20 weeks (100 mg/kg ketamine hydrochloride/10 mg/kg xylazine IP), bled retroorbitally, perfused transcardially with 1x PBS, and hearts fixed in 4% paraformaldehyde (Sigma) and embedded in paraffin. Livers, aortic arch, and thoracic aorta were snap-frozen in liquid N 2 and stored at −80ºC. 
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Atherosclerotic Lesion Analyses
Serial cross-sections (5-μm thick) were taken throughout the entire aortic root for histological analyses as described. 26, 27 Briefly, aortic cross-sections were stained with hematoxylin-phloxine-saffron and atherosclerotic lesion area was analyzed in 4 cross-sections/ mouse. Aperio Imagescope (Leica Biosystems) and ImageJ were used for morphometric quantification of lesion number, area, and severity according to the American Heart Association 26,27 classification. MAC-3 (CD107b; 550292; BD-Pharmigen) and α-SMA (61001; Progen, Germany) antibodies were used to determine macrophage and smooth muscle actin content. Sections were stained with Picrosirius red (365548; Sigma) for collagen content.
Matrix Metallopeptidase Activity Assays
The aortic arch was dissected, snap-frozen, and homogenized in RIPA (radioimmunoprecipitation assay) buffer. Twenty micrograms protein was mixed with SDS-Tris-glycine sample buffer without a reducing agent, loaded onto a precast 10% SDS-polyacrylamide gel containing 1 mg/mL gelatin (EC6175BOX; Thermo Fisher Scientific), and samples electrophoresed according to manufacturer's protocol (Thermo Fisher Scientific). Mouse recombinant MMP2 (matrix metallopeptidase 2; 554402; Biolegend) and MMP9 (755202; Biolegend) were used as positive controls. Digested bands were quantified by ImageJ software.
Carotid Artery Wire Injury Model of Vascular Remodeling
Male, 10 to 12-week-old Apoe −/− mice (C57BL/6J background) from Charles River Laboratory (Italy) maintained on 12-hour dark/light cycle and fed an atherogenic high-fat diet (21% fat, 0.15% cholesterol; Altromin) for 1 week before and 2 weeks after injury were anaesthetized (100 mg/kg ketamine hydrochloride/10 mg/kg xylazine IP) and subjected to endothelial denudation of the left common carotid artery by a 1 cm insertion of a flexible 0.36-mm guidewire through a transverse arteriotomy of the external carotid artery, as described. 28 For the inhibitor studies, Apoe −/− mice were continuously treated with FURIN inhibitor α-1-PDX (20 μg/kg per day) via Alzet osmotic minipumps, subcutaneously implanted 1 day before injury. For the recombinant FURIN expression studies, 2 units of purified human recombinant FURIN (P8077; New England Biolabs, MA) in 20 nmol/L HEPES per mouse was injected 3× per week, intraperitoneally, beginning on the day of wire injury. At 2 weeks after injury, the mice were euthanized and perfused in situ with 4% paraformaldehyde. The injured carotid arteries were isolated, fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Serial 4-μm transverse sections (9 sections/ mouse, 40 μm apart) were collected within a distance of 0 to 320 μm from the bifurcation, stained using Elastica-van Gieson, and areas of lumen, neointima (between lumen and internal elastic lamina), and media (between internal and external elastic laminae) were measured by planimetry using Diskus Software (Hilgers). For each mouse, data from the 9 sections were averaged to represent lesion formation along this standardized distance. Neointimal macrophages, smooth muscle cells, and endothelial cells were visualized by immunofluorescence staining for MAC-2 (Galectin-3; M3/38; Cedarlane), SMA (smooth muscle actin; 1A4; Dako), or CD31 (cluster of differentiation 31; M-20; Santa Cruz Biotechnology), respectively, followed by fluorescein isothiocyanate (FITC)-conjugated or Cy3-conjugated secondary antibody staining (Jackson ImmunoResearch) as described. 29, 30 Animal studies were approved by local authorities and complied with German animal protection law and also approved by the Biomedical Sciences Institute Singapore Institutional Animal Care Committee.
Cell Culture and Differentiation
THP-1 (Tohoku Hospital Pediatrics-1) cells were differentiated using 10 ng/mL phorbol 12-myristate-13-acetate (Sigma-Aldrich) for 48 hours, then in RPMI1640 (10% FCS, 1% L-glutamine) for 24 hours. For experiments with THP-1-activated monocytes, cells were stimulated with 100 ng/mL of lipopolysaccharide (LPS-EB Ultrapure; InvivoGen) for 4 hours. FURIN activity assays were performed in THP-1 monocytes and phorbol 12-myristate-13-acetate-differentiated macrophages after 24-hour incubation in the absence or presence of lipopolysaccharide (100 ng/mL) following manufacturer's instructions (New England Biolabs).
Primary human coronary artery endothelial cell line from ATCC (Manassas, VA) was cultured in EndoGRO-VEGF Complete Culture Media (Merck, Kenilworth, NJ) supplemented with 20% FBS, heparin, endothelial cell growth factor, nonessential amino acids, and antibiotics. Human coronary artery endothelial cell line cells (100 000) were placed in 12 well plates and treated with 25 μM Decanoyl-RVKR-CMK (dec-CMK; Merck), recombinant human TNF-α (20 ng/mL, BioLegend), or dec-CMK followed by TNF-α.
Real-Time Reverse TranscriptionPolymerase Chain Reaction
Total RNA was prepared using NucleoSpin RNA Mini kit (MachereyNagel), and cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-RAD). Real-time polymerase chain reaction (PCR) analyses were performed on an Applied Biosystems Viia 7 instrument, with PrecisionFASTTM 2X quantitative PCR Mastermix (PrimerDesign). PCR runs included a 2-minute preincubation at 95°C, followed by 50 cycles consisting of 95°C for 5 s, 64°C for 5 s, and 72°C for 10 s. After completion of PCR, a melting curve and Cq value were analyzed. Primer sequences are available on request.
Statistical Analyses
Data were analyzed using GraphPad Prism (Prism version 7, GraphPad Software). D'Agostino's K 2 and Shapiro-Wilk tests were applied to determine the normality of the data. If the data passed the normality tests, differences between 2 groups were analyzed using Student t test. If data did not pass normality, Mann-Whitney tests were applied to check for significant differences. One-way ANOVA was used to determine the significant differences for multiple group comparisons, followed by a Tukey post hoc test. For nonparametric multiple comparisons, Kruskal-Wallis tests were used. Dose-response curves of FURIN activity in cultured cells were generated via the DRC software in R, based on a 4-parameter log-logistic model. 31 Values of P<0.05 were considered to represent significant differences between groups. Results are shown as mean±SEM.
Results
Genetic and Genomic Evidence Support a Role for FURIN in Atherosclerosis
Pathway enrichment analyses of genome-wide association studies had previously identified 32 Reactome pathways as replicably associated with CAD. 4 Analyses of pathway interrelationships via sharing of gene components identified FURIN as a central component of 6 CAD-associated Reactome pathways, 32 including degradation of the extracellular matrix, extracellular matrix organization, posttranslational modification (gamma carboxylation, hypusine formation, and arylsulfatase activation), signaling by PDGF (platelet-derived growth factor), signaling by NOTCH, and signaling by TGF-β receptor complex ( Figure 1A ). These findings suggest a possible role for FURIN in vascular remodeling (via extracellular matrix modulation 33 and PDGF signaling pathways 34 ), inflammation and cellular infiltration (via Notch and PDGF signaling 34, 35 ), and regulation of plaque stability (via TGF-β signaling 36 ), thereby affecting both early-and late-stage atherosclerotic processes. To evaluate additional evidence for FURIN's potential involvement in atherosclerosis, we screened large-scale gene expression data from the Gene Expression Omnibus 37 for human studies relevant to atherosclerosis, from which 18 microarray studies encompassing 570 samples were retrieved and analyzed. FURIN was highly expressed in all 4 The results for FURIN are highlighted in the black-bordered rectangle. Heatmap is colorcoded by the negative logarithm of the CAD-association P values for the respective genes. B, Expression of FURIN in genome-scale expression datasets in Gene Expression Omnibus. Expression of FURIN and other PCSKs (proprotein convertase subtilisin/kexin family members) were quantified in 570 samples encompassing vascular endothelial cells (EC), vascular smooth muscle cells (VSMC), monocyte/macrophages (Macrophage), and human atherosclerotic plaques (Plaque). To allow comparisons between disparate experiments, gene expression levels were converted to quantiles (quintiles) with quintile 1 (Q1) representing the top 20% expressed genes. HDL indicates high-density lipoprotein; HLH, hemophagocytic lymphohistiocytosis; HS, heparan sulfate; NCAM, neural cell adhesion molecule; PDGF, platelet-derived growth factor; PPARA, peroxisome proliferator-activated receptor alpha; PTM, post-translational modification; SMAD, mothers against decapentaplegic homolog; and TGF, transforming growth factor. atherosclerosis-relevant cell types ( Figure 1B ) and in atherosclerotic plaques. Of all proprotein convertases tested, FURIN expression was most consistently high in all atherosclerosisrelevant cell types, including plaques. This finding is also consistent with other published data showing high FURIN levels in atherosclerotic plaques. 38 
FURIN Inhibition Decreases Monocyte Migration and Monocyte/Macrophage and Vascular Endothelial Inflammatory Gene Expression In Vitro
Because our Reactome pathway analyses suggested a potential role for FURIN in inflammation and cellular infiltration, we first assessed if FURIN plays a role in monocyte migration. Dose-response curves for FURIN inhibition in monocytes, macrophages, and human coronary artery endothelial cells were determined by treating cells with varying concentrations of the irreversible, cell-permeable, and competitive FURIN inhibitor Decanoyl-RVKR-CMK 39 ( Figure I in the online-only Data Supplement). In transwell migration assays, the migration of lipopolysaccharide activated monocytes was significantly decreased in the presence of Decanoyl-RVKR-CMK (Figure 2A ), demonstrating that FURIN facilitates the transmigration of monocytes. The decreased number of transmigrated monocytes was not a result of increased cell death in the inhibitor-treated group ( Figure 2B) . To determine the impact of FURIN inhibition on inflammatory and adhesion molecule expression, we assessed gene expression levels. In monocytes, the expression of the adhesion molecule VCAM-1 (vascular cell adhesion molecule 1) was significantly reduced in the presence of the inhibitor ( Figure 2C ). No changes were observed in the expression of the inflammatory markers CCL2 (C-C motif chemokine ligand 2), NF-κB (nuclear factor kappa B subunit 1), and IL1-β, as well as the adhesion molecule, ICAM-1 (intercellular adhesion molecule 1; Figure 2C ). Under lipopolysaccharide-stimulated inflammatory conditions in monocytes, a significant inhibition of ICAM-1 and IL1-β expression was observed ( Figure 2D ), suggesting that FURIN inhibition may reduce monocyte inflammatory cytokine and adhesion molecule expression during atherogenesis. In macrophages, the expression of CCL2, VCAM-1, and ICAM-1 were all reduced in the presence of the FURIN inhibitor ( Figure 2E ), suggesting that inflammatory chemokine, cytokine, and adhesion molecule expression may also be significantly decreased by FURIN inhibition in lesional macrophages. We next assessed the response of FURIN to lipopolysaccharide elicited inflammation and found a significant decrease in macrophage FURIN activity ( Figure 2F ). This decrease in FURIN activity was not observed in monocytes on lipopolysaccharide stimulation ( Figure 2F ). Together, these data show that FURIN modulates monocyte recruitment and transmigration and regulates monocyte and macrophage response to inflammatory stimulation.
We next assessed the impact of FURIN inhibition on TNF-α stimulated vascular endothelial cells because FURIN is expressed in and plays a critical role in endothelial cell function. 40 A significant reduction in NF-κB, CCL2, IL1-β, and VCAM-1 expression was observed ( Figure II in the online-only Data Supplement), whereas no changes in ICAM-1 expression were observed. These data suggest that FURIN inhibition may protect against inflammatory stimulation in both monocyte/macrophages and vascular endothelial cells during atherosclerosis.
Lower Plasma FURIN Levels in FURIN Inhibitor-Treated Mice
Because our in silico analyses showed FURIN to be a hub gene in CAD-associated pathways, its levels were elevated in atherosclerotic plaques, and our in vitro studies suggested FURIN inhibition may be atheroprotective, we next assessed if FURIN plays a role in atherosclerotic lesion development in vivo. We utilized α-1-PDX, a peptide inhibitor of FURIN that functions as a suicide substrate that irreversibly binds to and causes the degradation of the FURIN protein. 21, 41 Male, 12-week-old Ldlr −/− mice on a WTD were injected thrice per week intraperitoneally with the FURIN inhibitor for 8 weeks.
To determine if FURIN inhibitor treatment has an effect on FURIN protein levels in vivo, we quantified plasma levels of FURIN in inhibitor-treated and vehicle-treated control mice. Compared with controls, circulating plasma levels of FURIN were significantly lower (59% decrease, P=0.002) in the FURIN inhibitor-treated mice, suggesting that indeed, administration of the FURIN inhibitor α-1-PDX resulted in reduced circulating FURIN levels ( Figure IIIA in the online-only Data Supplement).
Lower Atherosclerotic Lesion Area and Severity in FURIN Inhibitor-Treated Ldlr −/− Mice
To determine the impact of FURIN inhibition on atherosclerotic lesion development, the WTD fed Ldlr −/− mouse model was utilized. 42 Atherosclerotic lesions were analyzed after 8 weeks of concurrent WTD and α-1-PDX administration in hematoxylin-phloxine-saffron stained sections of the aortic sinus. A trend toward lower total lesion area in the FURIN inhibitortreated group was observed (FURIN Figure 3A and 3B). Lesions were then categorized using the American Heart Association classification system as mild (class I to III) or severe (classes IV and V). 26, 27 No change in the area of mild lesions was observed (FURIN Figure 3D ) suggesting that in the Ldlr −/− hypercholesterolemic model, FURIN inhibition reduced the formation of more mature lesions.
FURIN Inhibition Reduces Atherosclerotic Lesion Complexity
Because an overall trend to lower lesion area, and a significant decrease in advanced lesion area, was observed in FURIN inhibitor-treated mice, we next assessed lesion complexity. Significantly lower (by 34%) macrophage (MAC-3)-positive lesion area was observed in the FURIN inhibitor-treated mice (FURIN inhibitor: 102.69±16.45, n=14; Control: 155.09±12.50×10 3 μm 2 , n=15; P=0.04; Figure 3E and 3F Figures 3G and 3H) , suggesting reduced lesional collagen in FURIN inhibitor-treated mice.
FURIN Inhibition Reduces Systemic Inflammation in Mice
Because treatment of the WTD fed Ldlr −/− mice with α-1-PDX resulted in reduced advanced lesion size and complexity, we next assessed levels of circulatory markers of inflammation in the mice. Plasma levels of the inflammation marker TNF-α were 44% lower in FURIN inhibitor-treated mice (FURIN inhibitor: 21.6±3.1, n=15; Control: 38.8±7.5 pg/mL, n=14; P=0.05; Figure 4A ). Similarly, plasma levels of the inflammation marker IL1-β were also significantly lower (by 66%) in the FURIN inhibitor-treated group (FURIN inhibitor: 13.9±2.8, n=15; Control: 40.8±8.9 pg/mL, n=14; P=0.01; Figure 4B ). Furthermore, we assessed levels of active TGF-β1, an inflammatory cytokine that plays a critical role in extracellular matrix degradation, which is also a substrate for FURIN. 43 Active TGF-β1 levels were significantly lower in the FURIN inhibitor-treated mice (FURIN inhibitor: 45.8±5.1, n=16; Control: 62.0±4.6 pg/mL, n=15; P=0.02; Figure 4C ), in line with our finding of lower lesional collagen in FURIN inhibitor-treated mice.
FURIN Inhibitor Treatment Results in Elevated Plasma HDL-Cholesterol Levels
Low levels of plasma apoB-containing lipoproteins are associated with atheroprotection, both in humans and in mice. 44 To determine if lipid levels were altered in the FURIN inhibitortreated hyperlipidemic Ldlr −/− mice, we quantified plasma lipids. Plasma LDLc (FURIN inhibitor: 28.4±1.9; Control: Figure 4D ).
FURIN Inhibition Reduces Matrix Metallopeptidase Activation
As a proprotein convertase, FURIN promotes the conversion of Pro-MMP2 to MMP2 via MT-1 MMP (membrane type 1 matrix metallopeptidase) activation. 45 In addition, the absence of MMP2 results in significant decreases in atherosclerotic lesions in Mmp2 −/− ×Apoe −/− mice. 46 Thus, we hypothesized that the inhibition of FURIN may have reduced atherosclerotic lesion progression in part via the inhibition of MMP2 activity. Indeed, as assessed by gelatin zymography, 47 levels of total MMP2 (FURIN inhibitor: 3530±749; Control: 11580±1919 densitometry arbitrary units, n=7 each; P=0.002; Figure 4E and 4F) and active/pro-MMP2 (FURIN inhibitor: 0.043±0.01; Control: 0.18±0.04 arbitrary units, n=7 each; P=0.01; Figure 4E and 4G) were significantly decreased in the aortic arch of FURIN inhibitor-treated mice. Although not shown to be a substrate for FURIN cleavage, MMP9 plays a role in atherosclerosis development, 48 and deficiency of MMP9 reduced atherosclerotic lesions in mice. 49 We observed no changes in MMP9 levels in the aortic arch of FURIN inhibitor-treated mice (FURIN inhibitor: 7359±1435; Control: 5482±542 arbitrary units, n=7 each; P=0.24; Figure V in the online-only Data Supplement), suggesting that FURIN inhibition reduced atherosclerotic lesions in part via the modulation of MMP2 but not MMP9 activity.
Lower Intima Thickening and Plaque Area in FURIN Inhibitor-Treated Apoe −/− Mice
Because our in silico genetic association and gene expression analyses implicated FURIN as a possible mediator of vascular remodeling in atherosclerosis, and MMP2 plays an important role in subendothelial basement membrane formation, 50 we next assessed the impact of FURIN inhibition in a wire injury model of vascular remodeling and restenosis. We administered α-1-PDX FURIN inhibitor via transplanted osmotic minipumps to WTD fed Apoe −/− mice in which the endothelium of the common carotid artery was injured with a flexible wire, an established model for the study of vascular remodeling in atherosclerosis. 51 Intimal lesions at the denuded regions were assessed in control and FURIN inhibitor-treated mice. Significantly lower (by 54%) intimal thickness (FURIN Figure 5A-5D ), suggesting that inhibition of FURIN resulted in significant protection from vascular restenosis and lesion formation in this mouse model.
Lower Plaque Cellularity, Macrophage Number and Inflammation in FURIN Inhibitor-Treated Mice
To determine if, in addition to the reduced lesion area, FURIN inhibition also resulted in reduced lesional macrophage number and inflammation, we assessed these parameters in the Apoe −/− wire injury model in vivo. Levels of the inflammatory marker TNF-α in the plaque were significantly lower (FURIN inhibitor: 17.5±2.0; Control: 25.8±2.4 arbitrary units/μm 2 , n=6 each; P=0.02; Figure 5E ) suggesting that FURIN inhibition reduces plaque inflammation. Levels of the endothelial adhesion molecule ICAM-1 (intercellular adhesion molecule 1) were not changed in FURIN inhibitor-treated mice ( Figure 5F ). Total cell number (FURIN inhibitor: 178.6±25.6; Control: 438.2±45.0 cells/plaque, n=6 each; P<0.0001; Figure 6A ), smooth muscle cell number (FURIN inhibitor: 22.4±3.7; Control: 54.2±6.3 cells/plaque, n=6 each; P=0.0001; Figure 6B ), and macrophage (MAC-2 + ) number (FURIN inhibitor: 74.9±13.5; Control: 127.5±16.8 cells/plaque, n=6 each; P=0.02; Figure 6C ) were significantly lower in atherosclerotic lesions of FURIN inhibitortreated mice. No significant differences in plaque endothelial cell numbers (CD31 + ) were observed ( Figure 6D ). Negative control isotype-specific immunoglobulin staining for these antibodies are shown in Figure VI in Figure 7E ) were observed.
Discussion
We show here that levels of the proprotein convertase FURIN are directly associated with atherosclerosis and restenosis, both in the hyperlipidemic Ldlr −/− model of atherosclerosis and in a carotid wire injury model of vascular endothelial remodeling. We find that systemic inhibition of FURIN prevented atherosclerosis progression in mice, in part, through the modulation of MMP2 activity.
In our Ldlr −/− mice, a significant reduction in severe lesions with no changes in early lesions was observed after FURIN inhibition, suggesting that FURIN might play a role in the later stages of lesion development. This is in line with the finding that FURIN was the most dysregulated primary PCSK in advanced atherosclerotic plaques, with a median RNA overexpression of ≈40-fold compared with nonatherosclerotic control samples. 38 As well, later stage, rupture-prone atherosclerotic lesions contain activated MMPs, including MMP2, 52 that weaken the plaque cap via extracellular matrix degradation. 52, 53 MMP2 is a FURIN substrate and is activated by FURIN. 45 Thus, the prevention of vascular MMP2 activation via FURIN inhibition may attenuate the development of severe lesions.
It is possible that reduced MMP2 levels are not the sole mechanism underlying the atheroprotective phenotypes we observe in the face of FURIN inhibition because FURIN has many protein substrates. However, Mmp2 −/− mice, when crossed to the Apoe −/− mice, show a significant reduction in atherosclerotic lesions at the aortic sinus, as well as significantly reduced macrophage and collagen content in aortic sinus lesions, 46 similar to our findings in the FURIN inhibitor-treated mice. In addition, no changes were observed in MMP9 levels in the Mmp2 −/− ×Apoe −/− mice, 46 similar to our findings that MMP9 levels are unaltered in the aortic arch of the FURIN inhibitor-treated mice. The reduced systemic inflammatory markers observed in the face of FURIN inhibition in our mice could also be modulated via the inhibition of MMP2 activity because the chemokine ligands CCL7 (C-C motif chemokine ligand 7) and CXCL-12 (C-X-C motif chemokine ligand 12) are substrates for MMP2 54, 55 and Mmp2 −/− mice display reduced allergic inflammation 56 suggesting a direct role for MMP2 in modulating inflammation. The curated FURIN substrate database, FurinDB (http:// www.nuolan.net), lists 87 mammalian substrates for FURIN. 57 These include many proteins with functions in the extracellular matrix, suggesting that one mechanism by which FURIN inhibition may reduce atherosclerotic lesions is via the regulation of the extracellular matrix, which plays a central role in tissue remodeling, as well as cell migration, cytokine, and chemokine recruitment, and adhesion receptor and cell surface proteoglycan recruitment at sites of lesions. 33 In line with a central role for FURIN in tissue remodeling, our data show that FURIN inhibition had a significant impact in reducing lesions in our model of vascular endothelial injury induced atherosclerosis.
Of interest, FURIN is a protease for PCSK9, 58 a critical regulator of LDLc metabolism, with an established role in atherosclerosis. 59 The accepted mechanism at present for PCSK9's role in LDLc metabolism and atherosclerosis is directly related to its role in the LDLR (LDL receptor) pathway. PCSK9 binds to LDLRs at the plasma membrane and targets them to lysosomes for degradation. 60 Since PCSK9 is a substrate for FURIN, to exclude a contribution by PCSK9 in our analyses of atherosclerosis, we chose the Ldlr −/− mouse model for part of our experiments. In addition, we saw no changes in plasma LDLc levels in our experiments. However, more recent studies on PCSK9 suggest that it may act in a paracrine manner in the arterial wall. 61 Thus, if PCSK9 might modulate atherosclerosis through LDLR independent mechanisms, and if FURIN might play a role in these mechanisms is unclear.
One potential caveat to our study was considered, which is the substrate specificity of the FURIN inhibitor, α-1-PDX. The α-1-PDX inhibitor was generated by mutating the reactivesite loop of α-1-antitrypsin to contain the minimal consensus sequence for FURIN cleavage, 62 resulting in the generation of an SDS-resistant complex with FURIN through its catalytic serine. 62 α-1-PDX displayed high selectivity for FURIN with Ki values as low as 600 pM 41 . However, at higher concentrations, α-1-PDX can also inhibit PC5/6 41 . If PC5/6 plays a role in atherosclerosis is unknown. As PC5/6 is expressed predominantly in the small intestine, kidney and lung of adult mice, 63 a direct effect of PC5/6 in atherosclerosis is unlikely.
Despite the partial nonspecificity of α-1-PDX, in biochemical, cellular and animal studies, α-1-PDX is well established to block FURIN activity. 64 To exclude the possibility that other proteins inhibited by α-1-PDX may have caused the observed reduction in atherosclerotic lesions in our experiments, and to directly confirm that FURIN alone can modulate atherosclerotic processes, we delivered FURIN protein to mice with a vascular endothelial injury in their carotid arteries and found a 67% increase in intimal lesion area in the face of FURIN overexpression, directly implicating a role for FURIN in lesion formation. Of note, the Arteriosclerosis, Thrombosis, and Vascular Biology Council recommends the use of both sexes in studies of atherosclerosis. 65 Only male mice were utilized here, which is a limitation of our study. Our findings suggest that FURIN inhibition may be beneficial for the inhibition of atherosclerosis and restenosis. The prevention of vascular MMP2 activation via FURIN inhibition may constitute an attractive mechanism to attenuate the development of severe lesions and may lead to increased plaque stability, thus representing a new therapeutic option for the treatment of atherosclerosis. Since advanced lesions leading to plaque rupture is the primary driver for CAD-related mortality, this possibility may have far-reaching clinical consequences. Furthermore, due to FURIN's role as an upstream activator of multiple substrates, inhibiting FURIN is likely to provide a broader benefit in lesion development, compared with targeting individual downstream effectors.
